Table 2 Subgroup analysis of pooled HRs for OS in cancer patients with abnormally expressed MLKL
| Subgroup analysis | No. of studies | Pooled HRs | Heterogeneity | |
|---|---|---|---|---|
| Fixed | I2 | p -value | ||
| Type of cancer | ||||
| Non-digestive system carcinoma | 3 | 0.22[0.11–0.44] | 0% | 0.866 |
| Digestive system carcinoma | 3 | 0.30[0.17–0.50] | 0% | 0.748 |
| Sample size | ||||
| < 100 | 3 | 0.23[0.11–0.46] | 0% | 0.806 |
| ≥ 100 | 3 | 0.28[0.17–0.48] | 0% | 0.704 |
| Follow-up time | ||||
| < 100 | 3 | 0.28[0.15–0.53] | 0% | 0.546 |
| ≥ 100 | 3 | 0.25[0.14–0.44] | 0% | 0.973 |
| NOS score | ||||
| < 7 | 2 | 0.20[0.08–0.51] | 0% | 0.627 |
| ≥ 7 | 4 | 0.28[0.18–0.46] | 0% | 0.873 |
